Clinical trials: Carcinoma Colon
Colon Cancer
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
- Trial name
- NCT04124406
- Testing
- Cologuard
- Where
- United States
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer, Metastatic Colon Cancer
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
The purpose of this study is to measure tumor response to treatment with ompenaclid (RGX-202-01) in patients with previously treated RAS mutant advanced or metastatic CRC.
- Trial name
- NCT05983367
- Testing
- Ompenaclid, Bevacizumab, FOLFIRI regimen
- Where
- 28 sites in Belgium, France and 1 more
- Volunteers
- 76 people
- Sponsor
- Inspirna, Inc.
Colon Cancer
Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer
Phase II study investigating the safety, tolerability and effect on disease reccurence of Foxy-5 as neo-adjuvant therapy in resected colon cancer patients treated with FOLFOX chemotherapy regimen.
- Trial name
- NeoFox (NCT03883802)
- Testing
- Foxy-5, FOLFOX regimen, Tumour resection (colon cancer surgery)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- WntResearch AB
Solid Tumor, Colorectal Cancer
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial
- Conditions
- Solid Tumor, Colorectal Cancer, Sigmoid Colon Cancer, Rectosigmoid Junction Cancer
- Trial name
- NCT05943041
- Testing
- GB104(Level 1), GB104(Level 2), GB104(Level 3)
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- GILongevity
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Metastatic Colorectal Cancer, Colon Cancer
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- COMPANION-003 (NCT05513742)
- Testing
- CTX-009
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Compass Therapeutics
Colorectal Carcinoma, Metastases
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: to evaluate the safety and any harmful effects of an intravenous injection of…
- Trial name
- NCT00107861
- Testing
- Ad.hIFN-β (BG00001, IDEC-201)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Biogen
Colon Polyps and Adenomas, Colon Cancer
Polyp Detection With The Peerscope System™
The PeerScope System consists of Peer Medical camera heads, endoscopes, video system, light source and other ancillary equipment.
- Trial name
- NCT01549535
- Testing
- Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- PeerMedical Ltd.
Colorectal Neoplasms
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of residual colorectal cancer following recent surgery.
- Trial name
- NCT00041691
- Testing
- hMN14 (labetuzumab)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Colonic Neoplasms, Colorectal Neoplasms
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
The primary objective is to assess and characterize the antitumor activity and safety and tolerability of adjuvant treatment with an individualized neoantigen vaccine called GRT-C901/GRT-R902 (chimpanzee adenovirus [ChAd] and…
- Trial name
- NCT05456165
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 3 sites in United States
- Sponsor
- Gritstone bio, Inc.
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.
- Trial name
- NCT07412613
- Testing
- Cadonilimab (AK104), Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Akeso
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Colorectal Cancer
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer.
- Trial name
- NCT01442155
- Testing
- Capecitabine, Oxaliplatin
- Where
- 9 sites in Slovakia
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC)
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer.
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Trial name
- NCT04844073
- Testing
- TAK-186
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 95 people
- Sponsor
- Takeda
Lung Cancer, Bronchial Cancer
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
24 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory advanced solid tumors.
- Conditions
- Lung Cancer, Bronchial Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT05886075
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Yunying Medical Technology